Abstract
A number of pharmacologic interventions are now recommended for the prevention of cardiovascular disease, based on the results of randomized controlled trials. These include antihypertensive drugs, lipid-lowering agents, antiplatelet and anticoagulant drugs, estrogen replacement therapy, beta-blockers, and angiotensin converting enzyme (ACE) inhibitors. It is likely that additional pharmacologic interactions will soon be proven efficacious. Despite the strength of this evidence and the development of clinical guidelines incorporating their use, a surprisingly low proportion of patients are actively treated with these agents. There may be a variety of explanations for this, including barriers at the level of the patient, health care provider, and health care institution. Finally, a number of questions remain as to the optimal combination of interventions, both behavioral and pharmacologic, which will yield maximal reduction in risk. The description of factors which reduce the effectiveness of pharmacologic interventions below the efficacy demonstrated in randomized clinical trials should be a fertile area for epidemiologic and behavioral research. *** DIRECT SUPPORT *** A00FV011 00007
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Smith SC, Blair SN, Criqui MH, et al: Preventing heart attack and death in patients with coronary disease.Circulation. 1995,92: 2–4.
Pearson TA, Marx HJ: Reduction of risk in the patient with cardiovascular disease. In Pearson TA Criqui MH, Luepker RV, Oberman A, Winston M (eds),Primer in Preventive Cardiology. Dallas, TX: American Heart Association, 1994, 235–237.
Vogel RA: Risk factor intervention and coronary artery disease: Clinical strategies.Coronary Artery Disease. 1995,6: 466–471.
Pearson TA, McBride PE, Houston-Miller N, Smith SC: Organization of preventive cardiology service.Journal of the American College of Cardiology. 1996,27: 1039–1047.
Forrester JF, Merz NB, Bush TL, et al: Task Force 4. Efficacy of risk factor management.Journal of the American College of Cardiology. 1996,27: 991–1006.
Collins R, Peto R, McMahon S, et al: Blood pressure, stroke, and coronary heart disease. Part 2. Short-term reductions in blood pressure: Overview of randomized drug trials in their epidemiological context.The Lancet. 1990,335: 827–839.
McMahon S, Peto R, Cutler J, et al: Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: Prospective studies corrected for regression dilution bias.The Lancet. 1990,335: 765–774.
SHEP Cooperative Research Group: Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension.Journal of the American Medical Association. 1991,265: 3255–3264.
McMahon S, Rodgers A: Blood pressure, antihypertensive treatment, and stroke risk.Journal of Hypertension. 1994,12(Suppl. 10): S5-S14.
Hebert PR, Moser M, Mayer J, Hennekens CH: Recent evidence on drug therapy of mild to moderate hypertension and decreased risk of coronary artery disease.Archives of Internal Medicine. 1993,153: 578–581.
The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V).Archives of Internal Medicine. 1993,153: 154–183.
Goldman L, Garber AM, Grover SA, Hlatky MA: Task Force 6. Cost effectiveness of assessment and management of risk factors.Journal of the American College of Cardiology. 1996,27(5): 1020–1030.
Littenberg B, Garber AM, Sox Jr. HJ: Screening for hypertension.Annals of Internal Medicine. 1990,112: 192–202.
Littenberg B: A practice guideline revisited: Screening for hypertension.Annals of Internal Medicine. 1995,122: 937–939.
Levine DM, Green LW, Deeds SG, et al: Health education for hypertensive patients.Journal of the American Medical Association. 1979,241: 1700–1703.
Morisky DE, Levine DM, Green LW, et al: Five-year blood pressure control and mortality following health education for hypertensive patients.American Journal of Public Health. 1983,73: 153–162.
Haynes RB, Dantes R: Patient compliance and the conduct and interpretation of therapeutic trials.Controlled Clinical Trials. 1987,8: 12–19.
Working Group on Health Education and High Blood Pressure Control:The Physicians Guide: Improving Adherence Among Hypertensive Patients. Bethesda, MD: U.S. Department of Health and Human Services, National Institutes of Health, 1987.
Levine DM, Cohen DJ, Dustan HP, et al: Behavior changes and the prevention of high blood pressure. Workshop II. AHA Prevention Conference III. Behavior change and compliance: Keys to improving cardiovascular health.Circulation. 1993,88: 1387–1390.
Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II).Journal of the American Medical Association. 1993,269: 3015–3033.
Rossouw JE: Secondary prevention of coronary heart disease. In Rifkin BM (ed),Lowering Cholesterol in High-Risk Individuals and Populations. New York: Marcel Dekker, 1995, 49–67.
Treasure CB, Klein JL, Weintraub WS, et al: Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease.New England Journal of Medicine. 1995,332: 481–487.
Anderson TJ, Meredith IT, Yeung AC, et al: The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion.New England Journal of Medicine. 1995,332: 488–493.
Egashira K, Hirooka Y, Kai H, et al: Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia.Circulation. 1994,89: 2519–2524.
Gould KL, Martucci JP, Goldberg DI, et al: Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by positron emission tomography after dipyridamole in patients with coronary artery disease.Circulation. 1994,89: 1530–1538.
Andrews TC, Raby K, Barry J, et al: The effect of LDL cholesterol reduction on myocardial ischemia in patients with coronary disease.Circulation. 1997,95: 324–327.
Brown GB, Zhao Y-Q, Sacco DE, et al: Lipid-lowering and plaque regression: New insights into prevention of plaque disruption and clinical events in coronary disease.Circulation. 1993,87: 1781–1789.
Post Coronary Artery Bypass Graft Trial Investigators: The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous vein coronary artery bypass grafts.New England Journal of Medicine. 1997,336: 153–162.
Scandinavian Simvastatin Survival Group: Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S).The Lancet. 1994,344: 1383–1389.
Sacks FM, Pfeffer MA, Moye LA, et al: The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels.New England Journal of Medicine. 1996,335: 1001–1009.
Shepherd J, Cobbe SM, Ford I, et al. for the West of Scotland Coronary Prevention Study Group: Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia.New England Journal of Medicine. 1995,333: 1301–1307.
Goldman L, Garber AM, Grover SA, Hlatky MA: Task Force 6. Cost effectiveness of assessment and management of risk factors.Journal of the American College of Cardiology. 1996,27: 1020–1030.
Giles WH, Anda RF, Jones DH, et al: Recent trends in the identification and treatment of high blood cholesterol by physicians. Progress and missed opportunities.Journal of the American Medical Association. 1993,269: 1133–1138.
Cohen MV, Byrne M-J, Levine B, Gutowski T, Adelson R: Low rate of treatment of hypercholesterolemia by cardiologists in patients with suspected and proven coronary artery disease.Circulation. 1991,83: 1294–1304.
Marcelino JJ, Feingold KR: Inadequate treatment with HMG-CoA reductase inhibitors by health care providers.American Journal of Medicine. 1996,100: 605–610.
Andrade S, Walker D, Gottlieb L, et al: Discontinuation of antihyperlipidemia drugs—Do rates reported in clinical trials reflect rates in primary care settings?New England Journal of Medicine. 1995,332: 1125–1131.
Simons LA, Levis G, Simon J: Apparent discontinuation rates in patients prescribed lipid-lowering drugs.Medical Journal of Australia. 1996,164: 208–211.
Antiplatelet Trialists' Collaboration: Collaborative overview of randomized trials of antiplatelet therapy-I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients.British Medical Journal. 1994,308: 81–106.
Cairns JA, Markham BA: Economics and efficacy in choosing oral anticoagulants or aspirin after myocardial infarction.New England Journal of Medicine. 1995,273: 965–967.
Patrono C: Aspirin as an antiplatelet drug.New England Journal of Medicine. 1994,330: 1287–1294.
Matchar DB, McCrory DC, Barnett HJM, Feussner JR: Medical treatment for stroke prevention.Annals of Internal Medicine. 1994,121: 41–53.
ISIS-2 (Second International Study of Infarct Survival) Collaborative Study Group: Randomized trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187, cases of suspected acute myocardial infarction: ISIS-2.The Lancet. 1988,2: 349–360.
Hirsh J, Dalen JE, Fuster VF, et al: Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects.Chest. 1995,108(Suppl.): 247S-257S.
Hart RG, Harrison MJG: Aspirin wars: The optimal dose of aspirin to prevent stroke.Stroke. 1996,27: 585–587.
Dyken ML, Barnett HJM, Easton JD, et al: Low-dose aspirin and stroke: “It ain't necessarily so.”Stroke. 1992,23: 1395–1399.
Patrono C, Roth GJ: Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen?Stroke. 1996,27: 756–760.
Cairns JA, Lewis HD, Meade TW, Sutton GC, Thèroux P: Antithrombotic agents in coronary artery disease.Chest. 1995,108(Suppl.): 380S-400S.
Smith P, Arnesen H, Holme I: The effect of warfarin on mortality and reinfarction after myocardial infarction.New England Journal of Medicine. 1990,323: 147–152.
Anticoagulation in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group: Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction.The Lancet. 1994,343: 499–503.
Laupacis A, Albers GW, Dalen JE, et al: Antithrombotic therapy for atrial fibrillation.Chest. 1995,108(Suppl.): 352S-359S.
Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials.Archives of Internal Medicine. 1994,154: 1449–1457.
Albers GW: Atrial fibrillation and stroke. Three new studies, three remaining questions.Archives of Internal Medicine. 1994,154: 1443–1448.
McCrory DC, Matchar DB, Samsa G, Sanders LL, Pritchett ELC: Physician attitudes about anticoagulation for non-valvular atrial fibrillation in the elderly.Archives of Internal Medicine. 1995,155: 277–281.
Agency for Health Care Policy and Research: Life-saving treatments to prevent stroke underused.Research Activities. 1995,187(September): 1–2.
Barrett-Connor E, Bush RL: Estrogen and coronary heart disease in women.Journal of the American Medical Association. 1991,265: 1861–1867.
Stampfer MH, Colditz GA: Estrogen replacement therapy and coronary heart disease: A quantitative assessment of the epidemiologic evidence.Preventive Medicine. 1991,20: 47–63.
Sullivan JM, Vander Zwaag R, Lemp GF, et al: Postmenopausal estrogen use and coronary atherosclerosis.Annals of Internal Medicine. 1988,108: 358–363.
Gruchow HW, Anderson AJ, Barboriak JJ, Sobocinski KA: Postmenopausal estrogen use of estrogen and occlusion of coronary arteries.American Heart Journal. 1988,115: 954–963.
McFarland KF, Boniface ME, Hornung CA, Barnhardt W, Humphries JO: Risk factors and non-contraceptive estrogen use in women with and without coronary disease.American Heart Journal. 1989,117: 1209–1214.
Sullivan JM, Vander Zwaag R, Hughes JP, et al: Estrogen replacement and coronary artery disease: Effects on survival in post menopausal women.Archives of Internal Medicine. 1990,150: 2557–2562.
O'Keefe JH, Kun SC, Hall RR, et al: Estrogen replacement therapy after coronary angioplasty.Journal of the American College of Cardiology. 1997,29: 1–5.
The Writing Group for the PEPI Trial: Effect of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial.Journal of the American Medical Association. 1996,273: 199–208.
Hennekens CH, Albert CM, Godfried SL, Gaziano JM, Buring JE: Adjunctive drug therapy of acute myocardial infarction. Evidence from clinical trials.New England Journal of Medicine. 1996,335: 1660–1667.
ASPIRE Steering Group: A British Cardiac Society survey of the potential for the secondary prevention of coronary disease: ASPIRE (Action in Secondary Prevention through Intervention to Reduce Events. Principal Results).Heart. 1996,75: 334–342.
Philbin EF, Andreou C, Rocco Jr. TA, Lynch LJ, Baker SL: Patterns of angiotensin converting enzyme inhibitor use in congestive heart failure in two community hospitals.American Journal of Cardiology. 1996,77: 832–838.
Furberg CD, Psaty BM, Meyer JV: Nifedipine: Dose-related increase in mortality in patients with coronary heart disease.Circulation. 1995,92: 1326–1331.
The Alpha-Tocophenol, Beta Carotene Cancer Prevention Study Group: The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers.New England Journal of Medicine. 1994,330: 1029–1035.
Stephen NG, Parson A, Schofield PM, et al: Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS).The Lancet. 1996,347: 781–786.
Berg JS, Dischler J, Wagner DJ, Raia JJ, Palmer-Shelvin N: Medication compliance: A health care problem.Annals of Pharmacotherapy. 1993,27(Suppl.): S2-S22.
Horwitz RI, Viscoli CM, Berkman L, et al: Treatment adherence and risk of death after a myocardial infarction.The Lancet. 1990,336: 542–545.
Gallagher EJ, Viscoli CM, Horwitz RI: The relationship of treatment adherence to the risk of death after myocardial infarction in women.Journal of the American Medical Association. 1993,270: 742–744.
Levine DM: Behavioral and psychosocial factors, processes, and strategies. In Pearson TA, Criqui MH, Luepker RV, et al (eds),Primer in Preventive Cardiology. Dallas, TX: American Heart Association, 1994, 217–226.
Eraker SA, Knight JP, Becker MH: Understanding and improving patient compliance.Annals of Internal Medicine. 1984,100: 258–268.
Luepker RV: Patient adherence: A “risk factor” for cardiovascular disease.Heart Disease and Stroke. 1993, 419–421.
The Pooling Project Research Group: Relationships of blood pressure, serum cholesterol, smoking habit, relative weight, and ECG abnormalities to incidence of major coronary events: Final report of the pooling project.Journal of Chronic Diseases. 1978,31: 201–306.
Avins AL, Browner WS: Lowering risk without lowering cholesterol: Implications for National Cholesterol Policy.Annals of Internal Medicine. 1996,125: 502–506.
Author information
Authors and Affiliations
About this article
Cite this article
Pearson, T.A., Feinberg, W. Behavioral issues in the efficacy versus effectiveness of pharmacologic agents in the prevention of cardiovascular disease. ann. behav. med. 19, 230–238 (1997). https://doi.org/10.1007/BF02892288
Issue Date:
DOI: https://doi.org/10.1007/BF02892288